Repaglinide - Revision history

Prab at 03:47, 22 March 2025

2025-03-22T03:47:21Z

← Older revision		Revision as of 03:47, 22 March 2025
Line 1:		Line 1:
			[[File:Repaglinide.svg\|Repaglinide\|thumb]]
			[[File:Repaglinide ball-and-stick.png\|Repaglinide ball-and-stick model\|thumb]]
	{{intro}}		{{intro}}
	Repaglinide is a benzoic acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of [[type 2 diabetes]].		Repaglinide is a benzoic acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of [[type 2 diabetes]].

	{{livtox}}		{{livtox}}
	Repaglinide has been linked to rare instances of clinically apparent acute liver injury.		Repaglinide has been linked to rare instances of clinically apparent acute liver injury.

	{{moa}}		{{moa}}
	Repaglinide (re pag' li nide) is an insulin secretagogue that is similar in action but different in structure from the sulfonylureas. It is a benzoid acid derivative that, like the sulfonylureas, stimulates insulin secretion by blocking ATP sensitive potassium channels in pancreatic beta-cells, causing cell membrane depolarization which results in calcium influx and insulin secretion. Repaglinide has been shown to reduce the postprandial increase in glucose in patients with [[type 2 diabetes]] and improve glycemic control. Repaglinide		Repaglinide (re pag' li nide) is an insulin secretagogue that is similar in action but different in structure from the sulfonylureas. It is a benzoid acid derivative that, like the sulfonylureas, stimulates insulin secretion by blocking ATP sensitive potassium channels in pancreatic beta-cells, causing cell membrane depolarization which results in calcium influx and insulin secretion. Repaglinide has been shown to reduce the postprandial increase in glucose in patients with [[type 2 diabetes]] and improve glycemic control. Repaglinide

	{{fda}}		{{fda}}
	{{PAGENAME}} was approved for use in the United States in 1997. The current indications are for management of [[type 2 diabetes]] used in combination with [[diet]] and [[exercise]], with or without other oral [[hypoglycemic agents]].		{{PAGENAME}} was approved for use in the United States in 1997. The current indications are for management of [[type 2 diabetes]] used in combination with [[diet]] and [[exercise]], with or without other oral [[hypoglycemic agents]].

	{{brand}}		{{brand}}
	Repaglinide is available generically and under the brand name [[Prandin]] in tablets of 0.5, 1 and 2 mg.		Repaglinide is available generically and under the brand name [[Prandin]] in tablets of 0.5, 1 and 2 mg.

	{{dose}}		{{dose}}
	The typical initial dose in adults is 0.5 mg three times daily before meals, with a gradual increase to a maximum of 16 mg daily.		The typical initial dose in adults is 0.5 mg three times daily before meals, with a gradual increase to a maximum of 16 mg daily.

	{{se}}		{{se}}
	Side effects of repaglinide include [[diarrhea]], [[nausea]], gastrointestinal upset, [[hypoglycemia]], [[headache]], [[dizziness]], arthralgia and [[rash]].		Side effects of repaglinide include [[diarrhea]], [[nausea]], gastrointestinal upset, [[hypoglycemia]], [[headache]], [[dizziness]], arthralgia and [[rash]].

	{{antidiabetic drugs}}		{{antidiabetic drugs}}
	{{coststubd}}		{{coststubd}}
	~~<gallery>~~		{{Oral hypoglycemics}}
	~~File~~:~~Repaglinide.svg\|Repaglinide~~		{{Ion channel modulators}}
	~~File~~:~~Repaglinide ball~~-~~and-stick.png\|Repaglinide ball-and-stick model~~		{{Portal bar \| Medicine}}
	~~</gallery>~~		[[Category:Potassium channel blockers]]
	~~<gallery>~~		[[Category:Meglitinides]]
	~~File~~:~~Repaglinide.svg\|Repaglinide~~		[[Category:1-Piperidinyl compounds]]
	~~File~~:~~Repaglinide ball-and-stick.png\|Repaglinide ball-and-stick model~~		[[Category:Phenol ethers]]
	~~</gallery>~~		[[Category:Acetamides]]
			[[Category:Benzoic acids]]
			[[Category:Ethoxy compounds]]
			[[Category:Drugs developed by Novo Nordisk]]
			[[Category:Isobutyl compounds]]

Prab: CSV import

2025-02-20T01:21:53Z

CSV import

← Older revision		Revision as of 01:21, 20 February 2025
Line 22:		Line 22:
	{{antidiabetic drugs}}		{{antidiabetic drugs}}
	{{coststubd}}		{{coststubd}}
			<gallery>
			File:Repaglinide.svg\|Repaglinide
			File:Repaglinide ball-and-stick.png\|Repaglinide ball-and-stick model
			</gallery>
	<gallery>		<gallery>
	File:Repaglinide.svg\|Repaglinide		File:Repaglinide.svg\|Repaglinide
	File:Repaglinide ball-and-stick.png\|Repaglinide ball-and-stick model		File:Repaglinide ball-and-stick.png\|Repaglinide ball-and-stick model
	</gallery>		</gallery>

Prab: CSV import

2025-02-20T01:11:23Z

CSV import

← Older revision		Revision as of 01:11, 20 February 2025
Line 22:		Line 22:
	{{antidiabetic drugs}}		{{antidiabetic drugs}}
	{{coststubd}}		{{coststubd}}
			<gallery>
			File:Repaglinide.svg\|Repaglinide
			File:Repaglinide ball-and-stick.png\|Repaglinide ball-and-stick model
			</gallery>

Prab: Created page with "{{intro}} Repaglinide is a benzoic acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabetes. {{livtox}} Repaglin..."

2019-04-26T15:09:18Z

Created page with "{{intro}} Repaglinide is a benzoic acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabetes. {{livtox}} Repaglin..."

New page

{{intro}}
Repaglinide is a benzoic acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of [[type 2 diabetes]].

{{livtox}}
Repaglinide has been linked to rare instances of clinically apparent acute liver injury.

{{moa}}
Repaglinide (re pag' li nide) is an insulin secretagogue that is similar in action but different in structure from the sulfonylureas. It is a benzoid acid derivative that, like the sulfonylureas, stimulates insulin secretion by blocking ATP sensitive potassium channels in pancreatic beta-cells, causing cell membrane depolarization which results in calcium influx and insulin secretion. Repaglinide has been shown to reduce the postprandial increase in glucose in patients with [[type 2 diabetes]] and improve glycemic control. Repaglinide

{{fda}}
{{PAGENAME}} was approved for use in the United States in 1997. The current indications are for management of [[type 2 diabetes]] used in combination with [[diet]] and [[exercise]], with or without other oral [[hypoglycemic agents]].

{{brand}}
Repaglinide is available generically and under the brand name [[Prandin]] in tablets of 0.5, 1 and 2 mg.

{{dose}}
The typical initial dose in adults is 0.5 mg three times daily before meals, with a gradual increase to a maximum of 16 mg daily.

{{se}}
Side effects of repaglinide include [[diarrhea]], [[nausea]], gastrointestinal upset, [[hypoglycemia]], [[headache]], [[dizziness]], arthralgia and [[rash]].

{{antidiabetic drugs}}
{{coststubd}}